Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma

Journal of Experimental & Clinical Cancer Research

Zhong-Ying Zhang⁴  Fen Wang³  Qing Hu²  Yuanhui Su²  Xianming Liang²  Zhang Dai²  Juan Li²  Pan You²  Lingqing Lin²  Hongwei Jin²  Hanyu You²  Huayue Lin²  Yongying Bai²  Jing Tang¹  Zanxi Fang² 

[1] General Hospital of the Yangtze River Shipping, Wuhan, China;Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China;Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX, USA;State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China

关键词: Diagnosis;    Biomarker;    Colorectal cancer;    Plasma;    microRNA;   

Others  :  1226282
DOI  :  10.1186/s13046-015-0198-6

 received in 2015-04-17, accepted in 2015-07-29,  发布年份 2015

【 摘 要 】

Background

MicroRNAs are stable and easy to detect in plasma. The plasma levels of microRNAs are often changed in disease conditions, including cancer. This makes circulating microRNAs a novel class of biomarkers for cancer diagnosis. Analyses of online microRNA data base revealed that expression level of three microRNAs, microRNA-24 (miR-24), microRNA-320a (miR-320a), and microRNA-423-5p (miR-423-5p) were down-regulated in colorectal cancer (CRC). However, whether the plasma level of these three microRNAs can serve as biomarkers for CRC diagnosis and prognosis is not determined.

Methods

Plasma samples from 223 patients with colorectal related diseases (111 cancer carcinoma, 59 adenoma, 24 colorectal polyps and 29 inflammatory bowel disease) and 130 healthy controls were collected and subjected to reverse transcription-quantitative real time PCR (RT-qPCR) analyses for the three microRNAs. In addition, plasma samples from 43 patients were collected before and after surgical treatment for the same RT-qPCR analyses.

Results

The concentrations of plasma miR-24, miR-320a and miR-423-5p were all decreased in patients with CRC and benign lesions (polyps and adenoma) compared with healthy controls, but increased in inflammatory bowel disease (IBD). The sensitivity of miR-24, miR-320a and miR-423-5p for early stage of CRC were 77.78 %, 90.74 %, and 88.89 %, respectively. Moreover, the plasma concentration of the three microRNAs was increased in patients after the surgery who had clinical improvement.

Conclusions

The plasma levels of miR-24, miR-320a, and miR-423-5p have promising potential to serve as novel biomarkers for CRC detection, especially for early stage of CRC, which are superior to the currently used clinical biomarkers for CRC detection, such as CEA and CA19-9. Further efforts to develop the three microRNAs as biomarkers for early CRC diagnosis and prediction of surgical treatment outcomes are warrant.

【 授权许可】

   
2015 Fang et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Zhang W, Zhang T, Jin R, Zhao H, Hu J, Feng B, et al.: MicroRNA-301a promotes migration and invasion by targeting TGFBR2 in human colorectal cancer. J Exp Clin Cancer Res 2014, 33:780.
• [2]Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C: CEA, CA 19–9 and CA 72–4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002, 22:2311-6.
• [3]Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006, 24:5313-27.
• [4]Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al.: Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008, 134:1570-95.
• [5]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-97.
• [6]Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-33.
• [7]Zhang M, Yang Q, Zhang L, Zhou S, Ye W, Yao Q, et al.: miR-302b is a potential molecular marker of esophageal squamous cell carcinoma and functions as a tumor suppressor by targeting ErbB4. J Exp Clin Cancer Res 2014, 33:10. BioMed Central Full Text
• [8]Liu M, Chen H: The role of microRNAs in colorectal cancer. J Genet Genom 2010, 37:347-58.
• [9]Dong Y, Wu WK, Wu CW, Sung JJ, Yu J, Ng SS: MicroRNA dysregulation in colorectal cancer: a clinical perspective. Br J Cancer 2011, 104:893-8.
• [10]Hrasovec S, Glavac D: MicroRNAs as novel biomarkers in colorectal cancer. Front Genet 2012, 3:180.
• [11]Ma R, Jiang T, Kang X: Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res 2012, 31:38. BioMed Central Full Text
• [12]Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al.: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-5.
• [13]Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-8.
• [14]Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al.: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
• [15]Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al.: Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3:e3148.
• [16]Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009, 112:55-9.
• [17]Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al.: Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58:1375-81.
• [18]Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, Banerjee D, et al.: MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One 2009, 4:e8445.
• [19]Zhang Y, He X, Liu Y, Ye Y, Zhang H, He P, et al.: microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. Oncol Rep 2012, 27:685-94.
• [20]Sun JY, Huang Y, Li JP, Zhang X, Wang L, Meng YL, et al.: MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting beta-catenin. Biochem Biophys Res Commun 2012, 420:787-92.
• [21]Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, et al.: MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis 2013, 34:530-8.
• [22]Zhao H, Dong T, Zhou H, Wang L, Huang A, Feng B, et al.: miR-320a suppresses colorectal cancer progression by targeting Rac1. Carcinogenesis 2014, 35:886-95.
• [23]Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, et al.: Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008, 54:482-90.
• [24]Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al.: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
• [25]Gao SM, Yang JJ, Chen CQ, Chen JJ, Ye LP, Wang LY, et al.: Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. J Exp Clin Cancer Res 2012, 31:27. BioMed Central Full Text
• [26]Zhou B, Chen H, Wei D, Kuang Y, Zhao X, Li G, et al.: A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res 2014, 33:55. BioMed Central Full Text
• [27]Liu J, Xue H, Zhang J, Suo T, Xiang Y, Zhang W, et al.: MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res 2015, 34:35. BioMed Central Full Text
• [28]Cheng Z, Wang HZ, Li X, Wu Z, Han Y, Li Y, et al.: MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNFAIP2 in Glioma. J Exp Clin Cancer Res 2015, 34:27. BioMed Central Full Text
• [29]Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al.: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-61.
• [30]Han ZB, Zhong L, Teng MJ, Fan JW, Tang HM, Wu JY, et al.: Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol 2012, 6:445-57.
• [31]Xie Y, Tobin LA, Camps J, Wangsa D, Yang J, Rao M, et al.: MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells. Oncogene 2013, 32:2442-51.
• [32]Gao Y, Liu Y, Du L, Li J, Qu A, Zhang X, et al.: Down-regulation of miR-24-3p in colorectal cancer is associated with malignant behavior. Med Oncol 2015, 32:362.
• [33]Cheng C, Chen ZQ, Shi XT: MicroRNA-320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthase. Tumour Biol 2014, 35:4177-83.
• [34]Wang X, Wu J, Lin Y, Zhu Y, Xu X, Xu X, et al.: MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6. J Exp Clin Cancer Res 2014, 33:69. BioMed Central Full Text
• [35]Sun JY, Xiao WZ, Wang F, Wang YQ, Zhu YH, Wu YF, et al.: MicroRNA-320 inhibits cell proliferation in glioma by targeting E2F1. Mol Med Rep 2015, 12(2):2355-9.
• [36]Wan LY, Deng J, Xiang XJ, Zhang L, Yu F, Chen J, et al.: miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun 2015, 457:125-32.
• [37]Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al.: A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011, 47:784-91.
• [38]Shida H, Ban K, Matsumoto M, Masuda K, Imanari T, Machida T, et al.: Asymptomatic colorectal cancer detected by screening. Dis Colon Rectum 1996, 39:1130-5.
• [39]Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al.: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348:1472-7.
• [40]Kitamura K, Taniguchi H, Yamaguchi T, Sawai K, Takahashi T: Clinical outcome of surgical treatment for invasive early colorectal cancer in Japan. Hepatogastroenterology 1997, 44:108-15.
• [41]Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, et al.: Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One 2014, 9:e92921.